Abstract
Treatment options for primary cutaneous aspergillosis in neonates are limited by the lack of pharmacokinetic and safety data of newer antifungal agents that are effective against Aspergillus spp. We report the successful treatment of cutaneous aspergillosis in an extremely low-birth-weight preterm infant with liposomal amphotericin B, voriconazole and micafungin, and provide pharmacokinetic profiles for voriconazole and micafungin.
Original language | English (US) |
---|---|
Pages (from-to) | 364-366 |
Number of pages | 3 |
Journal | Pediatric Infectious Disease Journal |
Volume | 26 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2007 |
Keywords
- Liposomal amphotericin B
- Micafungin
- Pharmacokinetic
- Preterm infant
- Primary cutaneous aspergillosis
- Voriconazole
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Microbiology (medical)
- Infectious Diseases